Major Investors Bet Big on Pfizer’s Turnaround Potential
Published on 11/29/2025 at 16:52 | Redaktion boerse-global.de
While Pfizer’s share price has shown limited movement in recent sessions, significant activity is unfolding behind the scenes. Prominent financial institutions are capitalizing on this apparent stagnation to make substantial purchases, repositioning their portfolios as market analysts begin to identify considerable upside potential. Is this strategic accumulation by sophisticated investors signaling a major trend reversal, or could retail investors be heading into a value trap?
Adding momentum to the institutional buying trend, the analytical firm Guggenheim has provided a fresh optimistic outlook. The firm’s analysts recently increased their price target to $35 while reaffirming their buy recommendation. This revised target suggests an approximate 36 percent Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
